Detalhe da pesquisa
1.
Navigating the complexity of pain in psoriatic arthritis and axial spondyloarthritis.
Curr Opin Rheumatol
; 36(4): 282-288, 2024 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38690783
2.
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
Lancet
; 401(10370): 25-37, 2023 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36493791
3.
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
Lancet
; 401(10370): 38-48, 2023 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36495881
4.
Improving the nosology of Long COVID: it is not so simple.
Ann Rheum Dis
; 83(1): 9-11, 2024 Jan 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37989548
5.
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023.
Ann Rheum Dis
; 83(4): 409-416, 2024 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38123338
6.
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.
Ann Rheum Dis
; 83(6): 706-719, 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38499325
7.
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis.
Rheumatology (Oxford)
; 2024 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38218744
8.
Patient clusters identified by machine learning from a pooled analysis of the clinical development programme of secukinumab in psoriatic arthritis, ankylosing spondylitis and psoriatic arthritis with axial manifestations.
Clin Exp Rheumatol
; 42(3): 696-701, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38019168
9.
The Burden of Work Productivity and Activity Impairment in Patients with Psoriasis, Psoriatic Arthritis, Ulcerative Colitis, and Crohn's Disease.
Dig Dis Sci
; 2024 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38811505
10.
Deucravacitinib for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
J Drugs Dermatol
; 23(2): 67-73, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38306122
11.
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.
Ann Rheum Dis
; 82(11): 1404-1414, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37696588
12.
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022.
Ann Rheum Dis
; 82(5): 594-598, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36702529
13.
Instrument selection for the ASAS core outcome set for axial spondyloarthritis.
Ann Rheum Dis
; 82(6): 763-772, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35680390
14.
Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE.
Rheumatology (Oxford)
; 62(2): 617-628, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35789257
15.
Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis.
Rheumatology (Oxford)
; 62(4): 1417-1425, 2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36102818
16.
Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis.
Rheumatology (Oxford)
; 62(2): 606-616, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35766811
17.
Efficacy of secukinumab on dactylitis in patients with active psoriatic arthritis from the FUTURE 5 study.
Clin Exp Rheumatol
; 41(3): 589-596, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35916290
18.
Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study.
Clin Exp Rheumatol
; 41(11): 2286-2297, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37404160
19.
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.
Ann Rheum Dis
; 81(6): 815-822, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35241426
20.
Secukinumab provides sustained improvement in nail psoriasis, signs and symptoms of psoriatic arthritis and low rate of radiographic progression in patients with concomitant nail involvement: 2-year results from the Phase III FUTURE 5 study.
Clin Exp Rheumatol
; 40(5): 952-959, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-34494957